merck & co. news - Search News

Is Merck & Co., Inc. (MRK) the Best Cheap Beginner Stock to Invest In?

We recently compiled a list of the 7 Cheap Beginner Stocks to Invest In. In this article, we will look at where Merck & Co., Inc. (NYSE:MRK) ranks among the cheap beginner stocks to invest in. Does Fed Rate Cut Translate to a Higher Consumer Borrowing Trend?

YAHOO!Finance · 1d

Merck & Co. Inc. (MRK): A Good Undervalued Blue Chip Stock to Buy According to Analysts

We recently compiled a list of the 7 Undervalued Blue Chip Stocks To Buy Right Now. In this article, we are going to take a look at where Merck & Co. Inc. (NYSE:MRK) stands against the other undervalued blue chip stocks.

Zacks.com on MSN · 1d

Merck (MRK) Stock Sinks As Market Gains: Here's Why

Merck (MRK) closed the latest trading day at $113.09, indicating a -1.43% change from the previous session's end. This change lagged the S&P 500's daily gain of 0.4%. Elsewhere, the Dow gained 0.62%,

Insider Monkey on MSN · 14h

Merck & Co., Inc. (MRK): An Undervalued Wide Moat Stock to Buy According to Analysts

We recently compiled a list of the 10 Undervalued Wide Moat Stocks to Buy According to Analysts. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other undervalued wide moat stocks.

Merck & Co. Inc. stock underperforms Thursday when compared to competitors

Shares of Merck & Co. Inc. MRK slipped 1.43% to $113.09 Thursday, on what proved to be an all-around favorable trading ...

FierceBiotech1d

Merck bags options on Evaxion's AI-designed vaccines, offering small upfront and big back end

Merck & Co. has picked up options on two Evaxion vaccine candidates, paying $3.2 million and dangling more than $1 billion in ...

This Is What Whales Are Betting On Merck & Co

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Merck's Experimental Favezelimab/Keytruda Combo Fails In Late-Stage Colorectal Cancer Study

Merck & Co Inc (NYSE:MRK) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of ...

FierceBiotech2d

Merck's Keytruda-LAG-3 combo fails to tame tough colorectal cancer in phase 3

An attempt by Merck & Co. to unlock the microsatellite stable (MSS) metastatic colorectal cancer market has ended in failure.

Morningstar2d

Merck says trial of combination treatment for colon cancer failed to meet main goal

Merck & Co.'s stock was flat on Wednesday, after the drug company said a late-stage trial of its blockbuster cancer drug Keytruda in combination with favezelimab failed to meet the main goal of ...

Merck Says Phase 3 KEYFORM-007 Study Did Not Meet Primary Goal Of Overall Survival

Merck & Co Inc. (MRK) on Wednesday said its Phase 3 KEYFORM-007 study evaluating the company's drug candidate favezelimab in ...

Merck & Co Unusual Options Activity For September 23

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer

Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult ...

Merck & Co. Inc. stock underperforms Monday when compared to competitors

Shares of Merck & Co. Inc. MRK shed 1.31% to $115.63 Monday, on what proved to be an all-around great trading session for the ...

3don MSN

Bristol, Merck checkpoint inhibitors focus of FDA advisory committee meeting

Opdivo (nivolumab) and Merck's (NYSE:MRK) Keytruda (pembrolizumab), two highly popular checkpoint inhibitors used in the ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results